Wednesday, July 28, 2010

The Green Revolution's field of dreams: India has grown a magnificent Cancer Market

by Mark Tillson.

There is great news out of India.

Indian oncology market to grow at 21% CAGR: F&S

The drug companies and medical establishment see great potential in "the market in cancer."

There are also new markets now in neurologic diseases, deformities, respiratory diseases, depression, etc.

This is what economists call "supplier-induced demand."

First the US opens India to multinational agribusiness which proceeds to poison India with pesticides, and then the drug companies move in to "help." But the companies are the same companies, first selling pesticide then eager to make money on cancer.

The inexorable business logic is clear.

The main principles governing the pharmaceutical "business with disease." It is not in the financial interests of the pharmaceutical industry to prevent common diseases – the maintenance and expansion of diseases is a precondition for the financial growth of this industry.

The pharmaceutical industry is an investment industry driven by the profits of its shareholders. Improving human health is not the driving force of this industry.

The pharmaceutical investment industry was artificially created and strategically developed over an entire century by the same investment groups that control the global petrochemical and chemical industries.

The huge profits of the pharmaceutical industry are based on the patenting of new drugs. These patents essentially allow drug manufacturers to arbitrarily define the profits for their products.

The marketplace for the pharmaceutical industry is the human body – but only for as long as the body hosts diseases. Thus, maintaining and expanding diseases is a precondition for the growth of the pharmaceutical industry. ....

The survival of the pharmaceutical industry is dependent on the elimination by any means of effective natural health therapies. These natural and non-patentable therapies have become the treatment of choice for millions of people despite the combined economic, political and media opposition of the world's largest investment industry.

And already, in Indian media, there are starting to be attacks on aryuvedic medicine and the natural (and harmless and cheap) treatments that India has given to the world, all the drugs companies are trying to patent (own) the very substances they promote as worthless natural treatments.

And suddenly there are plans now for quickly trained doctors to go to villages (no one cared about the villages before), to diagnose and prescribe treatments.

Foreign companies planted fields of disease under the name, "the Green Revolution."

Now the same companies are returning to harvest the crop, under the name "modern medicine for poor backward India." The crop will yield immense profits. To help, the government of India is opening the door to a Second Green Revolution. More pesticides and now even GMOs would be planted, so ever larger crops of deformity, developmental disability, neurologic diseases, skin diseases, heart diseases, sterility, endlessly diverse cancers, and human agony can grow and flourish.

Indian oncology market to grow at 21% CAGR: F&S

Bangalore, July 27, 2010: The Indian oncology market is witnessing strong growth alongside fast-paced development in the pharmaceutical sector. The market is expected to grow at a CAGR of 21 percent from 2008 to 2014, driven by the introduction of new treatments, increasing number of patients on chemotherapy, and improved access to modern cancer therapies, according to a new report from Frost & Sullivan (F&S).

Cancer is one of the 10 leading causes of death in India. Nearly half the cases are curable if detected early. Due to the high prevalence of cancer, the oncology market is witnessing fast-paced growth. High spending on therapeutic drugs for cancer in the emerging economies including India is fuelling market growth.

"With the expanding base of patients undergoing chemotherapy in the major markets and greater access to modern therapies, cancer drugs are poised for widespread uptake," noted an F&S analyst, adding: "Moreover, the increase in the aging population is another factor contributing positive momentum for the market." A 40 to 50 percent increase in incidences can be seen for some of the major cancer indications such a prostate, breast, ovarian, and head and neck cancers. Also the high prevalence of smoking is loading to the proliferation in the number of patients afflicted with lung cancer.

Trends indicate that the incidence of cancer is set to assume dangerous proportions in the future, making the disease one of the major chronic diseases that will continue to impact people's lives. Going forward, greater progress in cancer therapy is envisioned along with more light being thrown on the cause of the disease. Yet, it remains to be seen how much the refinement in the present detection diagnostic, and therapeutic technologies will help in containing the spread of the disease. Large quantities of generic drugs are available in the market for cancer treatment. Chemotherapy is highly genericized, said the F&S report, pointing out that these products are low-priced and hence place restrictions on potential revenues.

In this market with increasing competition and generic players, it is important to strategically position products as early in their life cycle as possible to generate the most revenue prior to patent expiration. For the competitive chemotherapy market, showing superior efficacy and less toxicity in combination with targeted therapy drugs is one of the best ways to distinguish the product over others.

"To be successful in the cancer market of the future, it is imperative for product to be established as an integral part of the standard combination therapy regimen. This will guarantee strong revenue and the most value to patients," said the analyst.

Identifying optimal drug combinations, which significantly increase median survival, tumor resolution and reduce toxicity and adverse effects should be the prime task for companies in the cancer therapeutic market, the report mentioned

No comments:

Post a Comment